{"filing":{"accession_number":"0001493152-26-031675","cik":"0001178697","ticker":"SONM","company_name":"DNA X, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226031675/form8-k.htm"},"events":[{"id":15720,"run_id":14016,"accession_number":"0001493152-26-031675","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"DNA X, Inc. entered into a securities purchase agreement on June 29, 2026 to issue 1,346,531 shares of Series B Convertible Preferred Stock in a private placement for $8.1 million (consisting of $5.0 million cash and $3.1 million debt cancellation) to DNA Holdings, a related party. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Material Definitive Agreement), and notes the shares will convert to Common Stock upon stockholder approval, creating significant dilution. The transaction also includes 2,494,000 additional Common Stock shares to be issued to consultants (DNA Holdings, Scott Walker, and Brock Pierce) contingent on stockholder approval, further evidencing dilutive equity issuance.","company_name":"DNA X, Inc.","ticker":"SONM","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":13599,"accession_number":"0001493152-26-031675","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"DNA X, Inc. entered into a securities purchase agreement on June 29, 2026 to issue 1,346,531 shares of Series B Convertible Preferred Stock in a private placement for $8.1 million (consisting of $5.0 million cash and $3.1 million debt cancellation) to DNA Holdings, a related party. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Material Definitive Agreement), and notes the shares will convert to Common Stock upon stockholder approval, creating significant dilution. The transaction also includes 2,494,000 additional Common Stock shares to be issued to consultants (DNA Holdings, Scott Walker, and Brock Pierce) contingent on stockholder approval, further evidencing dilutive equity issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:56:37.700321+00:00","company_name":"DNA X, Inc.","ticker":"SONM","filing_date":"2026-07-02"}]}